Menopause Therapy
Nov 07, 2025
Bayer’s Lynkuet Ushers in New Class of Therapies for Menopause
After a brief delay earlier this year, and following its world-first approval in the UK over the summer, Bayer has now secured FDA approval for its novel therapy, expanding the limited range of nonhormonal options available for managing common menopausal symptoms. The FDA has approved Bayer’s dual neurokinin (NK) i...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
